Nanotech could be the next frontier of drug delivery

Nanoparticles (NPs) are defined as materials with dimensions smaller than 100 nm and presenting various shapes, i.e., spheres, rods, dendritic shapes, etc. This definition is accepted by the European Union (EU) Commission. It should be noted, however,

Nanoparticles are particles that are smaller than 100 nanometer (1/10,000 millimeter) which is about 40,000 times thinner than a hair. There are two forms of nanoparticles: soluble and biodegradable nanoemulsions such as liposomes and insoluble nanopigments

During the past few years, nanoparticles have been increasingly present in our everyday lives. To gain a better understanding of their health impacts, several studies have focused on the effects they have on our bodies and

Nanotechnology is an innovative area of science that includes the design, characterization, production, and application of materials, devices and systems by controlling shape and size at the nanometer scale (1–100 nm). Nanotechnology incorporation in cosmetic formulation

Conventional therapies in cancer treatment face challenges in delivery of drugs in the body and just the quantity needed, due to the toxic nature of the medicines used that have unwanted side effects. Nanomaterials have ‘enormous’

As part of the ongoing Govt of India initiative “Azadi ka Amrit Mahatosav”, the Indian Journal of Biochemistry and Biophysics (IJBB), CSIR-National Institute of Science Communication and Policy Research (NIScPR), New Delhi, has brought out its

Nanotechnology for Nutricosmetics Nanocarriers are ubiquitous within nanomedicine; however, with skin quality and health in high demand for consumers, these fields have overlapped. The use of nanotechnology and nanoformulations as delivery systems for improving the performance

Nanotechnology is the science of manipulating atoms and molecules in the nanoscale – 80,000 times smaller than the width of a human hair. The world market for products that contain nanomaterials is expected to reach $2.6

Alzheimer’s disease (AD) is a complex neurodegenerative disease that leads to insidious deterioration of brain functions. Current treatments for AD that focus on inhibition of amyloid beta (Aβ) aggregation failed to show effectiveness in people with